{
    "clinical_study": {
        "@rank": "92676", 
        "brief_summary": {
            "textblock": "The purpose of this research study is to test the safety and effectiveness of inhaled\n      Interferon gamma-1b (IFN-g 1b), when administered for 48 weeks and in combination with oral\n      antibiotics which may be administered for up to 72 weeks for the treatment of a lung\n      infection caused by a bacterium called Mycobacterium avium complex .\n\n      FDA has not approved Interferon gamma-1b for use in patients with MAC infection of the\n      lungs, which is the purpose of this study.Interferon gamma-1b and similar proteins play\n      important roles in establishing and maintaining protective immune responses against a\n      variety of microorganisms."
        }, 
        "brief_title": "Safety and Efficacy of Inhaled Interferon Gamma-1b in Pulmonary MAC Infection", 
        "completion_date": {
            "#text": "February 2003", 
            "@type": "Actual"
        }, 
        "condition": "Lung Infection", 
        "condition_browse": {
            "mesh_term": "Mycobacterium avium-intracellulare Infection"
        }, 
        "detailed_description": {
            "textblock": "Laboratory research has shown that a mouse form of interferon gamma is effective in treating\n      mice with infections caused by bacteria similar to MAC as well as MAC infection."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Male and female patients, 18 years of age or older, with bacteriologically and\n        radiographically confirmed pulmonary MAC infection who have been treated for their\n        infection for at least 6 months within the previous 2 years, as well as patients with\n        moderate or severe pulmonary disease due to MAC, not previously treated for this\n        infection.  Patients with recurrent pulmonary MAC infection after previous successful\n        treatment for pulmonary MAC disease are also eligible.\n\n        In addition, various laboratory testing must confirm conditions.  Patients cannot be\n        positive for HIV or have an extra-pulmonary (in general, outside of the lungs) infection\n        of MAC.  Other preconditions related to health or other conditions exist as factors for\n        inclusion or exclusion from this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 7, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00043355", 
            "org_study_id": "GIMAC-001"
        }, 
        "intervention": {
            "description": "500 mcg, oral, three times weekly", 
            "intervention_name": "interferon gamma-1b", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-gamma", 
                "Interferons"
            ]
        }, 
        "keyword": [
            "pulmonary", 
            "mycobacterium avium complex infection", 
            "MAC", 
            "nontuberculous", 
            "mycobacteria", 
            "lung"
        ], 
        "lastchanged_date": "October 30, 2007", 
        "number_of_arms": "1", 
        "official_title": "A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Safety and Efficacy of Inhaled Interferon Gamma-1b With Antimycobacterials in Previously Treated or Mod-to-Sev Pulmonary Mycobacterium Avium Complex Infection", 
        "overall_official": {
            "affiliation": "InterMune", 
            "last_name": "Steven Porter, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_outcome": {
            "measure": "sustained culture conversion", 
            "time_frame": "52 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00043355"
        }, 
        "source": "InterMune", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "InterMune", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2000", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2007", 
        "why_stopped": "Futility"
    }, 
    "geocoordinates": {}
}